GlassScriptPhysician profile
Anna Joan Kavanaugh
NPI 1962827345
$2,613.03
in general payments reported to CMS, 2019-2025
22 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.07 · 2022: $142 · 2023: $572 · 2024: $810 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.66 |
| Education | $236.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $533.13 | 2023-2025 | Dupixent |
| Csl Behring | $295.99 | 2022-2025 | Haegarda, Hizentra, Andembry |
| Genzyme Corporation | $236.63 | 2023-2025 | |
| Galderma Laboratories, L.P. | $223.22 | 2025 | Nemluvio |
| Amgen INC. | $190.78 | 2022-2025 | Tezspire |
| Blueprint Medicines Corporation | $165.52 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $149.16 | 2021-2025 | Xolair |
| Glaxosmithkline, LLC. | $135.11 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Pharming Healthcare, INC. | $103.76 | 2023-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $96.94 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $95.21 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Biocryst US Sales Co., LLC | $73.39 | 2023-2024 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $70.13 | 2021-2025 | Takhzyro |
| Abbvie INC. | $62.43 | 2021-2022 | |
| Optinose US, INC. | $50.83 | 2022-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $31.07 | 2023 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $27.61 | 2025 | Neffy |
| Octapharma USA, INC. | $18.56 | 2024 | Cutaquig |
| Lilly USA, LLC | $14.43 | 2024 | Ebglyss |
| Grifols USA, LLC | $14.29 | 2024 | Prolastin-C Liquid |
| Covis Pharma Gmbh | $13.08 | 2022 | |
| Lundbeck LLC | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kavanaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.